DIASTOLIC LEFT VENTRICULAR DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION IN ELDERLY

Authors

  • CALENICI Oleg Hospital Centre, Department of Normandy
  • CARAUSH Alexandr IMSP Institutul de Cardiologie, Clinica ,,Hipertensiuni arteriale”
  • MOISEEVA Anna IMSP Institutul de Cardiologie, Clinica ,,Hipertensiuni arteriale”
  • COCIU Maria IMSP Institutul de Cardiologie, Clinica ,,Hipertensiuni arteriale”
  • UNTURA Ludmila IMSP Centrul Republican de Diagnosticare Medicală
  • CARAUSH Mihaela IMSP Centrul Republican de Diagnosticare Medicală

DOI:

https://doi.org/10.52692/1857-0011.2022.1-72.20

Keywords:

Congestive heart failure, preserved left ventricular systolic function, diastolic function

Abstract

Congestive heart failure with preserved left ventricular systolic function is termed “diastolic heart failure” and is more prevalent in the older population, may account for one half of the older population with congestive heart failure, and may be more common in women than men. The prognosis of patients with congestive heart failure due to diastolic dysfunction is less ominous than in patients with systolic dysfunction yet the morbidity can be high with frequent treatment failures and hospital readmissions.Conclusions: Thus, the diagnosis of heart failure with preserved ejection fraction (HFpEF) on elderly (≥ 85 years old) patients is cumbersome. Diagnosis of heart failure with preserved ejection fraction is challenging in euvolemic patients with dyspnea, and no evidence-based criteria are available. Diastolic LV dysfunction is very common parameter (58 %), but without any specificity for HFpEF, its treatments should be focused on the underlying disease etiology as well as on the derangement in left ventricular diastolic function.

Author Biographies

CALENICI Oleg, Hospital Centre, Department of Normandy

MD, PhD; Lillebonne, France;

CARAUSH Alexandr, IMSP Institutul de Cardiologie, Clinica ,,Hipertensiuni arteriale”

 dr. hab. șt. med., profesor cercetător

MOISEEVA Anna, IMSP Institutul de Cardiologie, Clinica ,,Hipertensiuni arteriale”

dr. șt. med, cercetător științific

COCIU Maria, IMSP Institutul de Cardiologie, Clinica ,,Hipertensiuni arteriale”

cercetător științific

UNTURA Ludmila, IMSP Centrul Republican de Diagnosticare Medicală

medic cardiolog

CARAUSH Mihaela, IMSP Centrul Republican de Diagnosticare Medicală

cercetător științific

References

McMurray J.J.V., Adamopoulos S., Anker S.D., et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur. J. Heart. Fail., 2012; 14:803–869.

Nagarakanti R., Ezekowitz M., Diastolic dysfunction and atrial fibrillation. J. Interv. Card Electrophysiol., 2008; 22:111–118.

Mancia G., Fagard R., Narkiewicz K., et al., 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 2013; 31:1281–1357.

Møller J.E., Whalley G.A., Dini F.L., et al., Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. Circulation., 2008; 117:2591–2598.

Wong L.S.M., van der Harst P., de Boer R.A., et al., Aging, telomeres and heart failure. Heart. Fail. Rev., 2010; 15:479–486.

Suzman R., Beard J.R., Boerma T., et al., Health in an ageing world-what do we know?. Lancet., 2014; 9967:484–486.

Rossi A., Faggiano P., Amado A.E., et al., Mitral and aortic valve sclerosis/calcification and carotid atherosclerosis: results from 1065 patients. Heart Vessels., 2014; 29:776–783.

Rossi A., Targher G., Zoppini G., et al., Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. Diabetes Care., 2012; 35:1781–1786.

Ferrari R., Böhm M., Cleland J.G.F., et al., Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur. J. Heart. Fail., 2015; 17:665–671.

Kristensen S., Jhund P., et al., Relative importance of history of heart failure hospitalization and N-terminal pro-B-type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Fail., 2015; 3:478–486.

Chioncel O., Lainscak M., Seferovic P., et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure LongTerm Registry. Eur J Heart Fail., 2017; 19:1574–1585.

Kabbach G, Mukherjee D. Pulmonary hypertension secondary to left disease. Curr Vasc Pharmacol. 2018; 16(6):555-560.

Naute J., Hummel Y., van der Meer P., et al., Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. Eur J Heart Fail., 2018; 20 (9): 1303-1311.

Hummel Y., Liu L., Lam C., et al., Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. Eur J Heart Fail., 2017; 19 (12): 1651-1660.

Rigolli M., Whalley G.A., Heart failure with preserved ejection fraction. J. Geriatr. Cardiol., 2013; 10:360– 376.

Zhang Y., Safar M.E., Iaria P., et al., Prevalence and prognosis of left ventricular diastolic dysfunction in the elderly: The PROTEGER Study. Am J Cardiol., 2010; 160:471–478.

Perk J., De Backer G., Gohlke H., et al., European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J., 2012; 33:1635– 1701.

Ikonomidis I., Aboyans V., Blacher J., et al., The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. Eur. J. Herat. Failure., 2019; 21:402-424.

Andersson C., Jonson A., Benjamin E., et al., 70year legacy of the Framingham Heart Study. Nature Review Cardiology., 2019; 16: 687-698.

Iturralde F., Gaasch W., Diagnostic criteria for diastolic heart failure. Progress in cardiovascular deseses., 2005; 5: 314-319.

Galderisi M., Lancellotti P., Donald E., et al., European multicentre validation study of the accuracy of E/e’ ratio in estimating invasive left ventricular filling pressure:EURO-FILLING study. Eur. Heart.J. Cardiovsc. Imaging., 2014; 15(7): 810-816.

Lancellotti P., Galderisi M., Edvardsen T., et al., Echo-Doppler estimation of left ventricular filling ptrssure: results of the multicentre EACVI Euro-Filling study. Eur Heart J, .2017; 18(19): 961-968.

Pieske B., Tschope C., de Boer R., et al., How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Herat Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J., 2019; 40 (40): 3297-3317.

Shan A., Cikes M., Prasad N., Echocardiographic features of patients with Herat Failure and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol., 2019; 10; 74(23):2858-2873.

Falcão-Pires I., Palladini G., Gonçalves N., et al., Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. Basic Res Cardiol., 2011; 106:801–814.

Palmiero P., Zito A., Maiello M., et al., Left ventricular diastolic function in hypertension: methodological considerations and clinical implications. J Clin Med Res., 2015; 7:137–144.

Lancellotti P., Henri C., The left atrium: an old ‘barometer’ which can reveal great secrets. Eur J Heart Fail., 2014; 16:1047–1048.

Rigolli M., Rossi A., Quintana M., et al., The prognostic impact of diastolic dysfunction in patients with chronic heart failure and post-acute myocardial infarction: Can age-stratified E/A ratio alone predict survival?. Int J Cardiol., 2015; 181:362–368.

Gazewood J., Turner P., Heart failure with Preserved Ejection Fraction: Diagnosis end Management. Am Fam Physician., 2017; 96 (9):582-588.

Henning R., Diagnostic and treatment of heart failure with preserved left ventricular ejection fraction. World J Cardiol., 2020; 12 (1): 7-25.

Duarte V., Caceres V., Daher N., et al., A novel agent in the treatment of heart failure with depressed systolic function. Arch Cardiol Mex., 2018; 88(4): 287-297.

Komajda M., Lam C.S., Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J., 2014; 35:1022–1032.

Solomon S., Rizkala A., Gong J., et al., Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail., 2017; 5:471–482.

Solomon S., Rizkala A., Lefkowitz M., et al., Baseline Characteristics of Patients with Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail., 2018; 11 (7), e004962.

Solomon S., Zile M., Pieske B., et al., Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet., 2012; 380:1387–1395.

McMurray J., Packer M., Desai A., et al., MRPARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med., 2014; 371:993–1004.

Pfeffer M., Claggett B., Assmann S., et al., Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation., 2015; 131:34–42.

Pitt B., Pfeffer M., Assmann S., et al., TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med., 2014; 370:1383–1392.

Kristensen S., Køber L., Jhund P., et al., International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation., 2015; 131:43–53.

Massie B., Carson P., McMurray J., et al., I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med., 2008; 359:2456–2467

Pocock S., Ariti C., McMurray J., et al., Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J., 2013; 34:1404–1413.

Katsi V., Georgiopoulos G., Laina A., et al., Left ventricular ejection fraction as therapeutic target: is it the ideal marker?. Heart Fail Rev., 2017; 22 (6):641-655

Martin N., Manoharan K., Thomas J., et al., Beta-blockers and inhibitors of the renin-angiotensin aldosteron system for chronic heart failure with preserved ejection fraction. Circ Heart Fail., 2016; 9(7): e003123.

Joyce E., Chung C., Badloe S., et al., Variable Contribution of Heart Failure to Quality of Life in Ambulatory Heart Failure With Reduced, Better, or Preserved Ejection Fraction. JACC Heart Fail., 2016; 4:184–193.

Downloads

Published

2022-04-08